stable PTH 7-34 Novasome(R) cream

[Jacob]

This is currently geared towards chemo patients.

http://www.medadnews.com/News/Index.cfm ... eid=439694

IGI and Boston University Collaborate in a Joint National Cancer Institute Study

BUENA, N.J.--(BUSINESS WIRE)--May 7, 2007 - IGI, INC. (AMEX:IG) announced that it has received, a STTR (Small Business Technology Transfer) grant from the National Cancer Institute to evaluate the safety and therapeutic potential of parathyroid hormone PTH (7-34) analog to treat alopecia (baldness) induced by chemotherapy in breast cancer patients. Alopecia is singled out by nearly 80% of patients as the most distressing side effect of cancer chemotherapy.

In the initial phase of animal testing, IGI successfully formulated PTH 7-34 into its proprietary Novasome(R) encapsulation technology, which, when applied to mice stimulated and maintained hair growth.

Under this grant, IGI will formulate a stable PTH 7-34 Novasome(R) cream and provide clinical samples to Boston University to study them in human subjects scheduled to receive chemotherapy. Michael Holick M.D. PhD is the Principal Investigator for this study.

Rajiv Mathur, President and CEO of IGI commented: "the use of peptide hormones, such as PTHrP, to treat skin disorders has been limited by the inability to deliver them topically. We believe that IGI's proprietary delivery technology provides a useful solution to this issue".

This report contains forward-looking statements relating to IGI's hopes and expectations for the future. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "will," "possible," "one time," "provides an opportunity," "continue" and similar expressions are intended to identify forward-looking statements. Such statements involve a number of risks and uncertainties and actual future events and results could differ materially from those indicated by such forward-looking statements due to general economic conditions, and the risk factors detailed in IGI's periodic reports and registration statements filed with the Securities and Exchange Commission.

Contact

IGI, Inc. Rajiv Mathur, 856-697-1441 ext. 102 President & Chief Executive Officer http://www.askigi.com

 

[bobs]

Interesting, nice find.

Two questions:

1)
could this be used by male pattern baldness-people?

2) a quote from the article:

"Rajiv Mathur, President and CEO of IGI commented: "the use of peptide hormones, such as PTHrP, to treat skin disorders has been limited by the inability to deliver them topically. We believe that IGI's proprietary delivery technology provides a useful solution to this issue". "

Isn't this what was/is the problem with NEOSH101 aswell?



I remember a girl in my class like eight years ago who had cancer and lost all her hair and wore a hat all the time.
It all grew out eventually but it felt painful for her I'm sure.

 

[Jacob]

1. Possibly

2. Yes, I think so.

Here's another that mentions only it's use for cancer patients again:

Currently, MRx—the parent company—is engaged in Phase Twostudies on MRx1024, a small-molecule compound that holds largepromise for cancer patients. In clinical trials, MRx1024 appears toprotect normal cells from damage during chemotherapy and radia-tion, yet does not interfere with anti-tumor activity in cancerouscells. As a result, it prevents a number of side effects of cancer treatment such as oral mucositis, hearing loss and alopecia"

http://www.techtransfer.umich.edu/about ... fy2005.pdf


Company website: http://www.moleculartherapeutics.com/home.htm